Linked Life Data

19690163

Source:http://linkedlifedata.com/resource/pubmed/id/19690163

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19690163rdf:typepubmed:Citationlld:pubmed
pubmed-article:19690163lifeskim:mentionsumls-concept:C0042071lld:lifeskim
pubmed-article:19690163lifeskim:mentionsumls-concept:C0016030lld:lifeskim
pubmed-article:19690163lifeskim:mentionsumls-concept:C0034830lld:lifeskim
pubmed-article:19690163lifeskim:mentionsumls-concept:C0151650lld:lifeskim
pubmed-article:19690163lifeskim:mentionsumls-concept:C0033414lld:lifeskim
pubmed-article:19690163lifeskim:mentionsumls-concept:C1145667lld:lifeskim
pubmed-article:19690163lifeskim:mentionsumls-concept:C0086982lld:lifeskim
pubmed-article:19690163lifeskim:mentionsumls-concept:C1879647lld:lifeskim
pubmed-article:19690163lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:19690163lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:19690163pubmed:issue42lld:pubmed
pubmed-article:19690163pubmed:dateCreated2009-10-12lld:pubmed
pubmed-article:19690163pubmed:abstractTextThe nicotinic acetylcholine receptor alpha1 (nAChRalpha1) was investigated as a potential fibrogenic molecule in the kidney, given reports that it may be an alternative urokinase (urokinase plasminogen activator; uPA) receptor in addition to the classical receptor uPAR. In a mouse obstructive uropathy model of chronic kidney disease, interstitial fibroblasts were identified as the primary cell type that bears nAChRalpha1 during fibrogenesis. Silencing of the nAChRalpha1 gene led to significantly fewer interstitial alphaSMA(+) myofibroblasts (2.8 times decreased), reduced interstitial cell proliferation (2.6 times decreased), better tubular cell preservation (E-cadherin 14 times increased), and reduced fibrosis severity (24% decrease in total collagen). The myofibroblast-inhibiting effect of nAChRalpha1 silencing in uPA-sufficient mice disappeared in uPA-null mice, suggesting that a uPA-dependent fibroblastic nAChRalpha1 pathway promotes renal fibrosis. To further establish this possible ligand-receptor relationship and to identify downstream signaling pathways, in vitro studies were performed using primary cultures of renal fibroblasts. (35)S-Labeled uPA bound to nAChRalpha1 with a K(d) of 1.6 x 10(-8) m, which was displaced by the specific nAChRalpha1 inhibitor d-tubocurarine in a dose-dependent manner. Pre-exposure of uPA to the fibroblasts inhibited [(3)H]nicotine binding. The uPA binding induced a cellular calcium influx and an inward membrane current that was entirely prevented by d-tubocurarine preincubation or nAChRalpha1 silencing. By mass spectrometry phosphoproteome analyses, uPA stimulation phosphorylated nAChRalpha1 and a complex of signaling proteins, including calcium-binding proteins, cytoskeletal proteins, and a nucleoprotein. This signaling pathway appears to regulate the expression of a group of genes that transform renal fibroblasts into more active myofibroblasts characterized by enhanced proliferation and contractility. This new fibrosis-promoting pathway may also be relevant to disorders that extend beyond chronic kidney disease.lld:pubmed
pubmed-article:19690163pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19690163pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19690163pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19690163pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19690163pubmed:languageenglld:pubmed
pubmed-article:19690163pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19690163pubmed:citationSubsetIMlld:pubmed
pubmed-article:19690163pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19690163pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19690163pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19690163pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19690163pubmed:statusMEDLINElld:pubmed
pubmed-article:19690163pubmed:monthOctlld:pubmed
pubmed-article:19690163pubmed:issn1083-351Xlld:pubmed
pubmed-article:19690163pubmed:authorpubmed-author:NgomN NNNlld:pubmed
pubmed-article:19690163pubmed:authorpubmed-author:EddyAllison...lld:pubmed
pubmed-article:19690163pubmed:authorpubmed-author:CollinsSarahSlld:pubmed
pubmed-article:19690163pubmed:authorpubmed-author:ZhangGuoqiang...lld:pubmed
pubmed-article:19690163pubmed:authorpubmed-author:ZhuWeizhongWlld:pubmed
pubmed-article:19690163pubmed:authorpubmed-author:LeboeufRenee...lld:pubmed
pubmed-article:19690163pubmed:authorpubmed-author:ThomasAlisonAlld:pubmed
pubmed-article:19690163pubmed:authorpubmed-author:SongYumeiYlld:pubmed
pubmed-article:19690163pubmed:authorpubmed-author:KernanKelly...lld:pubmed
pubmed-article:19690163pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19690163pubmed:day16lld:pubmed
pubmed-article:19690163pubmed:volume284lld:pubmed
pubmed-article:19690163pubmed:ownerNLMlld:pubmed
pubmed-article:19690163pubmed:authorsCompleteYlld:pubmed
pubmed-article:19690163pubmed:pagination29050-64lld:pubmed
pubmed-article:19690163pubmed:dateRevised2010-12-17lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:meshHeadingpubmed-meshheading:19690163...lld:pubmed
pubmed-article:19690163pubmed:year2009lld:pubmed
pubmed-article:19690163pubmed:articleTitleA novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis.lld:pubmed
pubmed-article:19690163pubmed:affiliationDivision of Nephrology, Immunology, Seattle Children's Hospital Research Institute, Seattle, Washington 98101, USA. guoqiang.zhang@seattlechildrens.orglld:pubmed
pubmed-article:19690163pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19690163pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:19690163pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
entrez-gene:11435entrezgene:pubmedpubmed-article:19690163lld:entrezgene
entrez-gene:18792entrezgene:pubmedpubmed-article:19690163lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19690163lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19690163lld:entrezgene